NDA 021799 · Sun Pharm Industries
Qualaquin
Quinine Sulfate · Oral
OrphanDiscontinuedLast checked: Nov 20, 2026Latest source record: Jun 19, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2005
Aug 12, 2005
Approved uses
1
Original approval plus efficacy supplements
Registered trials
49
9 Phase 3, 2 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 12, 2005 Original approval · Type 5 - New Formulation or New Manufacturer OrphanReviewMedication GuideLabel
1 products under this application
- QUALAQUIN · QUININE SULFATE 324MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · CAPSULE, ORAL · Discontinued · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Quinine" as an intervention, any sponsor and status, largest first.
University of OxfordAcademic, hospital or other
NCT04093765 · 5,542 participants · Start Nov 1, 2018 · Primary completion Dec 31, 2019
Drug: Antimalarials · For: Plasmodium Falciparum Malaria
Sites: Mae Sot, Thailand
- Impact of Artemisinin-based Combination Therapy and Quinine on Treatment Failure and Resistance in Uncomplicated MalariaPivotal-lookingCompleted
Universiteit AntwerpenAcademic, hospital or other
NCT01374581 · 2,117 participants · Start May 2012 · Primary completion Jun 2014
Drug: Artemether/Lumefantrine; Artesunate/Amodiaquine and 1 more · For: Malaria
Sites: Kinshasa, Republic of the Congo; Kiruhura, Uganda
- Safety of Antimalarials in the FIRst trimEsterPivotal-lookingRecruiting
Liverpool School of Tropical MedicineAcademic, hospital or other
NCT06962319 · 1,510 participants (planned) · Start Sep 30, 2025 · Primary completion Aug 2028
Drug: dihydroartemisinin-piperaquine (DP); Pyronaridine-artesunate (PA) and 1 more · For: Malaria, Pregnancy; Malaria, Antepartum; Malaria (Uncomplicated)
Sites: Nanoro, Burkina Faso; Kisumu, Kenya; Bamako, Mali
- Post-discharge Malaria Chemoprevention(PMC) StudyPivotal-lookingCompleted
Liverpool School of Tropical MedicineAcademic, hospital or other
NCT02671175 · 1,049 participants · Start May 20, 2016 · Primary completion Oct 24, 2018
Drug: dihydroartemisinin-piperaquine; dihydroartemisinin-piperaquine placebo · For: Malaria; Severe Anemia
Sites: Homa Bay, Kenya; Migori, Kenya; Siaya, Kenya · 9 sites in all
- Cotrifazid Safety and Efficacy Against MalariaPivotal-lookingTerminated
Center for Primary Care and Public Health (Unisante), University of Lausanne, SwitzerlandAcademic, hospital or other
NCT00322907 · 330 participants · Start Apr 2000
Drug: Cotrifazid vs mefloquine or quinine+SP · For: Clinical Malaria
Sites: Madang and Maprik, Papua New Guinea
- Effectiveness of Oral Quinine and Artemether-Lumefantrine in the Treatment of Uncomplicated Malaria in Ugandan ChildrenPivotal-lookingStatus unknown
Makerere UniversityAcademic, hospital or other
NCT00540202 · 302 participants (planned) · Start Sep 2007
Drug: artemether-lumefantrine; Oral quinine · For: Uncomplicated Malaria
Sites: Kampala, Uganda
- Antimalaria Drugs Susceptibility Testing for an Effective Management of Infected Patients in Sub-Sahara AfricaPivotal-lookingCompleted
University of BamendaAcademic, hospital or other
NCT02974348 · 300 participants · Start Jan 2013 · Primary completion May 2013
Drug: Arthemeter-lumefantrine; Artesunate mefloquine and 4 more · For: Drug Resistant Malaria Due to Plasmodium Falciparum
Sites: Tiko, Cameroon
- Quinine vs. Artemether/Lumefantrine in Uncomplicated Malaria During PregnancyPivotal-lookingCompleted
EpicentreAcademic, hospital or other
NCT00495508 · 300 participants · Start Oct 2006 · Primary completion Jun 2009
Drug: Quinine; artemether / lumefantrine · For: Malaria
Sites: Mbarara, Uganda
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Leg cramps.
Young G · BMJ Clin Evid 2015 · Systematic Review
- Leg cramps.
Young G · BMJ Clin Evid 2009 · Systematic Review
- Artemether for severe malaria.
Esu EB, Effa EE, Opie ON, et al. · Cochrane Database Syst Rev 2019 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Artemether for severe malaria.
Esu E, Effa EE, Opie ON, et al. · Cochrane Database Syst Rev 2014 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Post-malaria neurological syndrome.
Nguyen TH, Day NP, Ly VC, et al. · Lancet 1996 · Clinical Trial, Multicenter Study
- Malaria: severe, life-threatening.
Sheehy SH, Angus BJ · BMJ Clin Evid 2011 · Systematic Review
Sponsor: Sun Pharm Industries
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.